Status:
RECRUITING
Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
Lead Sponsor:
Xiangtan Central Hospital
Collaborating Sponsors:
Second Xiangya Hospital of Central South University
ZhuZhou Central Hospital
Conditions:
Anemia
Heart Failure
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart ...
Detailed Description
Study Description Brief Summary: The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-ca...
Eligibility Criteria
Inclusion
- Male or female between the ages of 18 and 100 years.
- Elevated NT-proBNP or BNP levels on admission.
- Ejection fraction of 50% or less, and New York Heart Association (NYHA) class II, III, or IV symptoms.
Exclusion
- Treatment with SGLT2-i during the past 3 months of admission,or previous intolerance of an SGLT2 inhibitor.
- Severe (eGFR \<30 mL/min/1.73 m\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization.
- Pregnant or breast feeding female patients.
Key Trial Info
Start Date :
August 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
1990 Patients enrolled
Trial Details
Trial ID
NCT04707261
Start Date
August 6 2021
End Date
January 1 2026
Last Update
July 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiangtan Central Hospital
Xiangtan, Hunan, China, 411100